Tower Bridge Advisors reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 2.8% during the 1st quarter, HoldingsChannel.com reports. The firm owned 201,917 shares of the biopharmaceutical company’s stock after selling 5,739 shares during the period. Tower Bridge Advisors’ holdings in Pfizer were worth $7,166,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Earnest Partners LLC bought a new stake in Pfizer during the 4th quarter valued at $105,000. First Dallas Securities Inc. bought a new stake in Pfizer during the 4th quarter valued at $118,000. Woodard & Co. Asset Management Group Inc. ADV bought a new stake in Pfizer during the 4th quarter valued at $118,000. Delpha Capital Management LLC bought a new stake in Pfizer during the 4th quarter valued at $126,000. Finally, Americafirst Capital Management LLC bought a new stake in Pfizer during the 3rd quarter valued at $127,000. Institutional investors own 69.43% of the company’s stock.
PFE has been the topic of several recent research reports. Jefferies Financial Group set a $39.00 target price on Pfizer and gave the company a “hold” rating in a research report on Monday, February 26th. BMO Capital Markets set a $43.00 target price on Pfizer and gave the company a “buy” rating in a research report on Tuesday, March 6th. Barclays cut Pfizer from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $41.00 to $38.00 in a research report on Thursday, April 5th. Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, April 6th. Finally, Berenberg Bank reaffirmed a “neutral” rating and set a $37.00 target price on shares of Pfizer in a research report on Wednesday, April 11th. Three equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and ten have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $40.27.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.03. The company had revenue of $12.91 billion during the quarter, compared to analyst estimates of $13.14 billion. Pfizer had a return on equity of 25.29% and a net margin of 41.29%. The firm’s quarterly revenue was up 1.0% on a year-over-year basis. During the same quarter last year, the business posted $0.69 EPS. equities research analysts expect that Pfizer Inc. will post 2.96 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Friday, June 1st. Investors of record on Friday, May 11th were paid a $0.34 dividend. The ex-dividend date of this dividend was Thursday, May 10th. This represents a $1.36 dividend on an annualized basis and a yield of 3.74%. Pfizer’s dividend payout ratio (DPR) is 51.32%.
In related news, EVP Laurie J. Olson sold 19,000 shares of the firm’s stock in a transaction on Wednesday, June 6th. The stock was sold at an average price of $36.45, for a total value of $692,550.00. Following the completion of the transaction, the executive vice president now owns 98,644 shares in the company, valued at approximately $3,595,573.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Ian C. Read sold 132,312 shares of the firm’s stock in a transaction on Tuesday, May 1st. The stock was sold at an average price of $36.01, for a total value of $4,764,555.12. The disclosure for this sale can be found here. Insiders sold a total of 156,535 shares of company stock valued at $5,647,222 in the last 90 days. 0.06% of the stock is currently owned by company insiders.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.